Learning to experience side effects after antidepressant intake – Results from a randomized, controlled, double-blind study

Psychopharmacology

Volumn 234, Issue 3, 2017, Pages 329-338

  Rheker, Julia ^a   Winkler, Alexander ^a   Doering, Bettina K ^a   Rief, Winfried ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Antidepressants; Learning; Nocebo; Side effects

Indexed keywords

AMITRIPTYLINE; PLACEBO; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONDITIONED REFLEX; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EVENING DOSAGE; FEMALE; HUMAN; HUMAN EXPERIMENT; LEARNING; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; YOUNG ADULT; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DEPRESSION; DIZZINESS; FATIGUE; MULTIVARIATE ANALYSIS; NOCEBO EFFECT; PSYCHOLOGY; XEROSTOMIA;

ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; CONDITIONING, CLASSICAL; DEPRESSIVE DISORDER; DIZZINESS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; LEARNING; MALE; MULTIVARIATE ANALYSIS; NOCEBO EFFECT; XEROSTOMIA; YOUNG ADULT;

EID: 84994213406     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4466-8     Document Type: Article

References (58)

1. Abbing-Karahagopian V, Huerta C, Souverein PC et al (2014) Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol 70:849–857. doi:10.1007/s00228-014-1676-z
2. Ader R, Mercurio MG, Walton J et al (2010) Conditioned pharmacotherapeutic effects: a preliminary study. Psychosom Med 72:192–197. doi:10.1097/PSY.0b013e3181cbd38b
3. Åkerblad A-C, Bengtsson F, von Knorring L, Ekselius L (2006) Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol 21:117–124
4. Albring A, Wendt L, Benson S et al (2012) Placebo effects on the immune response in humans: the role of learning and expectation. PLoS One 7:e49477. doi:10.1371/journal.pone.0049477
5. Amanzio M (2015) Nocebo effects and psychotropic drug action. Expert Rev Clin Pharmacol 8:159–161. doi:10.1586/17512433.2015.992877
6. Amanzio M, Corazzini LL, Vase L, Benedetti F (2009) A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 146:261–269. doi:10.1016/j.pain.2009.07.010
7. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C (2005) Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp 66:96–106. doi:10.1016/j.curtheres.2005.04.006
8. Attwood A, Terry P, Higgs S (2010) Conditioned effects of caffeine on performance in humans. Physiol Behav 99:286–293. doi:10.1016/j.physbeh.2009.11.004
9. Barnhart ER (ed) (1988) Physician’s desk reference, 42nd edn. Medical Economics Company, Oradell, NJ
10. Barsky A, Saintfort R, Rogers M, Borus J (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287:622–627
11. Beck A, Ward C, Medelson M et al (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571
12. Benkert O, Hippius H (2014) Kompendium der psychiatrischen Pharmakotherapie, 10th edn. Springer, Berlin, Heidelberg
13. Bingel U (2014) Avoiding nocebo effects to optimize treatment outcome. JAMA 312:693–694. doi:10.1001/jama.2014.8342.Conflict
14. Bocquier A, Cortaredona S, Verdoux H et al (2014) Social inequalities in early antidepressant discontinuation. Psychiatr Serv 65:618–625. doi:10.1176/appi.ps.201300184
15. Cleare A, Pariante CM, Young AH et al (2015) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 29:459–525. doi:10.1177/0269881115581093
16. Cohen S (2014) The nocebo effect of informed consent. Bioethics 28:147–154. doi:10.1111/j.1467-8519.2012.01983.x
17. Colloca L, Miller FG (2011) The nocebo effect and its relevance for clinical practice. Psychosom Med 73:598–603. doi:10.1097/PSY.0b013e3182294a50
18. Colloca L, Sigaudo M, Benedetti F (2008) The role of learning in nocebo and placebo effects. Pain 136:211–218. doi:10.1016/j.pain.2008.02.006
19. Colloca L, Petrovic P, Wager T et al (2010) How the number of learning trials affects placebo and nocebo responses. Pain 151:430–439
20. De las Cuevas C, Peñate W, Sanz EJ (2014) Risk factors for non-adherence to antidepressant treatment in patients with mood disorders. Eur J Clin Pharmacol 70:89–98. doi:10.1007/s00228-013-1582-9
21. Derogatis LR (1994) Symptom checklist-90-revised: administration, scoring and procedures manual, 2nd edn. National Computer Systems, Minneapolis (MN)
22. Doering BK, Rief W (2012) Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol Sci 33:165–172. doi:10.1016/j.tips.2011.12.001
23. Doering BK, Rief W (2013) Nocebos in daily clinical practice. In: Colloca L, Flaten MA, Meissner K (eds) Placebo and pain: from bench to bedside. Academic Press, pp 257–266
24. Enck P, Bingel U, Schedlowski M, Rief W (2013) The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 12:191–204
25. Faul F, Erdfelder E, Lang A-G, Buchner A (2007) G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191
26. Goebel MU, Meykadeh N, Kou W et al (2008) Behavioral conditioning of antihistamine effects in patients with allergic rhinitis. Psychother Psychosom 77:227–234. doi:10.1159/000126074
27. Haddad PM, Anderson IM (2007) Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat 13:447–457. doi:10.1192/apt.bp.105.001966
28. Hiller W, Zaudig M, Mombour W (2004) Internationale Diagnose Checklisten für ICD-10 und DSM-IV, 2nd edn. Verlag Hans Huber, Bern
29. Hung C-I, Wang S-J, Liu C-Y et al (2011) Comorbidities and factors related to discontinuation of pharmacotherapy among outpatients with major depressive disorder. Compr Psychiatry 52:370–377. doi:10.1016/j.comppsych.2010.08.005
30. Jeffrey GR, Harrison W, Quitkin FM, Klein DF (1986) How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res 19:75–86
31. Jensen KB, Kaptchuk TJ, Kirsch I et al (2012) Nonconscious activation of placebo and nocebo pain responses. Proc Natl Acad Sci U S A 109:15959–15964. doi:10.1073/pnas.1202056109
32. Klosterhalfen S, Kellermann S, Braun S et al (2009) Gender and the nocebo response following conditioning and expectancy. J Psychosom Res 66:323–328. doi:10.1016/j.jpsychores.2008.09.019
33. Kramer JC, Klein DF, Fink M (1961) Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 118:449–550
34. Lockhart P, Guthrie B (2011) Trends in primary care antidepressant prescribing 1995–2007. Br J Gen Pract:565–572. doi:10.3399/bjgp11X593848.e565
35. Margraf J, Ehlers A, Roth WT et al (1991) How “blind” are double-blind studies? J Consult Clin Psychol 59:184–187. doi:10.1037/0022-006X.59.1.184
36. Matteson S, Roscoe J, Hickok J, Morrow GR (2002) The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol 186:S239–S243. doi:10.1067/mob.2002.122597
37. Mitsikostas DD (2012) Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep 12:132–137. doi:10.1007/s11910-011-0245-4
38. Mojtabai R, Olfson M (2014) National trends in long-term use of antidepressant medications. J Clin Psychiatry 75:169–177. doi:10.4088/JCP.13m08443
39. Mondaini N, Gontero P, Giubilei G et al (2007) Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 4:1708–1712. doi:10.1111/j.1743-6109.2007.00563.x
40. Murata A, Kanbayashi T (2012) Risk factors for drug nonadherence in antidepressant-treated patients and implications of pharmacist adherence instructions for adherence improvement. Patient Prefer Adherence 863–869
41. Nestoriuc Y, Orav EJ, Liang MH et al (2010) Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res (Hoboken) 62:791–799. doi:10.1002/acr.20160
42. Pavlov IP (2010) Conditioned reflexes: an investigation of the physiological activity of the cerebral cortex. Ann Neurosci 17:136–141
43. Perahia DG, Kajdasz DK, Desaiah D, Haddad PM (2005) Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 89:207–212. doi:10.1016/j.jad.2005.09.003
44. Rief W, Avorn J, Barsky AJ (2006) Medication-attributed adverse effects in placebo groups—implications for assessment of adverse effects. Arch Intern Med 166:155–160
45. Rief W, Nestoriuc Y, von Lilienfeld-Toal A et al (2009) Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials. Drug Saf 32:1041–1056
46. Rief W, Barsky AJ, Glombiewski JA et al (2010) Assessing general side effects in clinical trials: reference data from the general population. Pharmacoepidemiol Drug Saf 20:405–415. doi:10.1002/pds
47. Rudorfer M, Potter W (1999) Metabolism of tricyclic antidepressants. Cell Mol Neurobiol 19:373–409
48. Sawada N, Uchida H, Suzuki T et al (2009) Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry 9:38. doi:10.1186/1471-244X-9-38
49. Schedlowski M, Enck P, Rief W, Bingel U (2015) Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacol Rev 67:697–730
50. Serna MC, Cruz I, Real J et al (2010) Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry 25:206–213. doi:10.1016/j.eurpsy.2009.07.012
51. Shedden Mora M, Nestoriuc Y, Rief W (2011) Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc Lond Ser B Biol Sci 366:1879–1888. doi:10.1098/rstb.2010.0394
52. Sihvo S, Wahlbeck K, Mccallum A et al (2010) Increase in the duration of antidepressant treatment from 1994 to 2003: a nationwide population-based study from Finland. Pharmacoepidemiol Drug Saf 19:1186–1193. doi:10.1002/pds
53. Sirey J, Meyers B (2014) Predictors of antidepressant prescription and early use among depressed outpatients. Am J Psychiatry 156:690–696
54. Solomon D, Keller M (2000) Multiple recurrences of major depressive disorder. Am J Psychiatry 157:229–233
55. Stewart-Williams S, Podd J (2004) The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull 130:324–340. doi:10.1037/0033-2909.130.2.324
56. von Blanckenburg P, Schuricht F, Albert U-S et al (2013) Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer 13:426. doi:10.1186/1471-2407-13-426
57. Winkler A, Rheker J, Doering BK, Rief W (2016) Conditioning of amitriptyline-induced REM sleep suppression in healthy participants: a randomized controlled trial. Psychophysiology. doi:10.1111/psyp.12695
58. (2015) http://www.pharmawiki.ch. http://www.pharmawiki.ch.